196 related articles for article (PubMed ID: 29388014)
21. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
22. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
[No Abstract] [Full Text] [Related]
23. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
[TBL] [Abstract][Full Text] [Related]
24. New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
Nguyen J; Saffari PS; Pollack AS; Vennam S; Gong X; West RB; Pollack JR
J Dent Res; 2022 Nov; 101(12):1517-1525. PubMed ID: 35689405
[TBL] [Abstract][Full Text] [Related]
25. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
Yan XC; Sun LS; Dong ZW; You Z; Dong Q
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
[TBL] [Abstract][Full Text] [Related]
26. The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review.
Malakar A; Kumar VR; Yadav P; Bhardwaj V; Barua CG; Bhardwaj G
Cureus; 2023 Oct; 15(10):e47682. PubMed ID: 38021761
[TBL] [Abstract][Full Text] [Related]
27. Loss of heterozygosity of the PTCH gene in ameloblastoma.
Farias LC; Gomes CC; Brito JA; Galvão CF; Diniz MG; de Castro WH; Bernardes Vde F; De Marco LA; Gomez RS
Hum Pathol; 2012 Aug; 43(8):1229-33. PubMed ID: 22221699
[TBL] [Abstract][Full Text] [Related]
28. DNA ploidy of ameloblastoma and ameloblastic carcinoma of the jaws. Analysis by image and flow cytometry.
Müller S; DeRose PB; Cohen C
Arch Pathol Lab Med; 1993 Nov; 117(11):1126-31. PubMed ID: 8239934
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma.
Kondo S; Ota A; Ono T; Karnan S; Wahiduzzaman M; Hyodo T; Lutfur Rahman M; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y
Cancer Med; 2020 Apr; 9(8):2904-2917. PubMed ID: 32096304
[TBL] [Abstract][Full Text] [Related]
30. Adenoid ameloblastoma with dentinoid is molecularly different from ameloblastomas and adenomatoid odontogenic tumors.
Coura BP; Dos Santos JN; Fonseca FP; Bernardes VF; de Aquino SN; Jorge Júnior J; Vargas PA; Romañach MJ; de Andrade BAB; Gomez RS; Gomes CC
J Oral Pathol Med; 2021 Nov; 50(10):1067-1071. PubMed ID: 34549835
[TBL] [Abstract][Full Text] [Related]
31. Differential Profile of Primary and Recurrent Ameloblastomas Among Afro-descendants and Non-Afro-descendants-a Systematic Review.
Patel P; Effiom OA; Akinshipo AO; Akintoye SO
J Racial Ethn Health Disparities; 2024 Feb; 11(1):92-100. PubMed ID: 36596981
[TBL] [Abstract][Full Text] [Related]
32. The long noncoding RNA KIAA0125 is upregulated in ameloblastomas.
Diniz MG; França JA; Vilas-Boas FAS; de Souza FTA; Calin GA; Gomez RS; de Sousa SF; Gomes CC
Pathol Res Pract; 2019 Mar; 215(3):466-469. PubMed ID: 30595406
[TBL] [Abstract][Full Text] [Related]
33. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.
You Z; Liu SP; Du J; Wu YH; Zhang SZ
J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659
[TBL] [Abstract][Full Text] [Related]
34. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
35. MicroRNAs expression profile in solid and unicystic ameloblastomas.
Setién-Olarra A; Marichalar-Mendia X; Bediaga NG; Aguirre-Echebarria P; Aguirre-Urizar JM; Mosqueda-Taylor A
PLoS One; 2017; 12(10):e0186841. PubMed ID: 29053755
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
37. Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres.
Bonacina R; Indini A; Massazza G; Rulli E; Gianatti A; Mandalà M;
J Clin Pathol; 2022 Aug; 75(8):555-559. PubMed ID: 33827932
[TBL] [Abstract][Full Text] [Related]
38.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
39. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
[TBL] [Abstract][Full Text] [Related]
40. Gnathic and peripheral ameloblastomas lack human papillomavirus DNA.
Verduin L; Bishop J; Mills SE
Ann Diagn Pathol; 2015 Oct; 19(5):306-9. PubMed ID: 26190154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
